Gene therapy returns to centre stage
The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Recent clinical trials of gene therapy have shown remarkable therapeutic benefits and an excellent safety record. They provide evidence for the long-sought promise of gene therapy to deliver 'cures' for some otherwise terminal or severely disabling conditions. Behind these advances lie improved vector designs that enable the safe delivery of therapeutic genes to specific cells. Technologies for editing genes and correcting inherited mutations, the engagement of stem cells to regenerate tissues and the effective exploitation of powerful immune responses to fight cancer are also contributing to the revitalization of gene therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation (allo-HSCT) can provide a one-time and life-long cure for patients with serious genetic hematological diseases such as primary immunodeficiencies20 and hemoglobinopathies21,22, if a suitable immunologically matched donor can be found23.”
From A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells (2018) · cites this paper as [23]
In the citing paper
“Although insertional mutagenesis risk has been reduced by improved vector design19, the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD20–23 has generated renewed concerns.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [19]
In the citing paper
“Gene therapy with autologous hematopoietic stem cells has been investigated as an alternative to allogeneic hematopoietic stem-cell transplantation.11–13”
From Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy (2017) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
In vivo genome editing using Staphylococcus aureus Cas9
Ran, F. A., Cong, L., Yan, W. X., Scott, D. A., Gootenberg, J. S., Kriz, A. J., Zetsche, B., Shalem, O., Wu, X., Makarova, K. S., et al. (2015) · Nature · doi:10.1038/nature14299 · Cited by 2,687
Hematopoietic Stem-Cell Transplantation
Copelan, E. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmra052638 · Cited by 2,522
Research works printed but not linked: 1
- Baxter. Baxalta reports continued progress on phase 1/2 clinical trial of BAX335, investigational gene therapy treatment for hemophilia B. Baxter http://www.baxter.com/news-media/newsroom/press-releases/2015/06_24_15_bax335.page (2015).
Cited by
Items 201–300 of 1,000
TLR9 signaling mediates adaptive immunity following systemic AAV gene therapy
Ashley, S. N., Somanathan, S., Giles, A. R., & Wilson, J. M. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.103997 · Cited by 67
Suzuki, K., Yamamoto, M., Hernández‐Benítez, R., Li, Z., Wei, C., Soligalla, R. D., Aizawa, E., Hatanaka, F., Kurita, M., Reddy, P., et al. (2019) · Cell Research · doi:10.1038/s41422-019-0213-0 · Cited by 73
Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease
Spencer Chapman, M., Cull, A. H., Ciuculescu, M. F., Esrick, E. B., Mitchell, E., Jung, H., O’Neill, L., Roberts, K., Fabre, M. A., Williams, N., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02636-6 · Cited by 67
“Although insertional mutagenesis risk has been reduced by improved vector design 19 , the development of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) at 3–5.5 years post-transplantation in 2 of 47 patients who had undergone GT for SCD 20–23 has generated renewed concerns.”
InfluentialNatural and artificial protein cages: design, structure and therapeutic applications
Heddle, J. G., Chakraborti, S., & Iwasaki, K. (2017) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.03.007 · Cited by 70
“These may be genetic (gene therapy [4]) or a host of other substances including drugs, inorganic materials and even functional proteins [5].”
BackgroundZhao, L., Rao, X., Zheng, R., Huang, C., Kong, R., Cheng, H. B., Li, B., & Li, S. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c01812 · Cited by 70
FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype
Arsenault, J., Gholizadeh, S., Niibori, Y., Pacey, L. K. K., Halder, S. K., Koxhioni, E., Konno, A., Hirai, H., & Hampson, D. R. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.090 · Cited by 80
Autism spectrum disorder: prospects for treatment using gene therapy
Benger, M., Kinali, M., & Mazarakis, N. D. (2018) · Molecular Autism · doi:10.1186/s13229-018-0222-8 · Cited by 80
Recent advancements in two‐dimensional nanomaterials for drug delivery
Mei, X., Hu, T., Wang, Y., Weng, X., Liang, R., & Wei, M. (2019) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1596 · Cited by 72
Highly branched poly(β-amino ester)s for gene delivery in hereditary skin diseases
Zeng, M., Xu, Q., Zhou, D., Sigen, A., Alshehri, F., Lara‐Sáez, I., Zheng, Y., Li, M., & Wang, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113842 · Cited by 69
Li, H., Zhang, Y., Shu, H., Lv, W., Su, C., & Nie, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121412 · Cited by 75
Six, E., Guilloux, A., Denis, A., Lecoules, A., Magnani, A., Vilette, R., Male, F., Cagnard, N., Delville, M., Magrin, E., et al. (2020) · Blood · doi:10.1182/blood.2019002350 · Cited by 65
Gene therapy for human osteoarthritis: principles and clinical translation
Madry, H., & Cucchiarini, M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1124084 · Cited by 66
“bly play a more important role,[166] as they allow for a direct and more durable targeting of the affected chon-”
BackgroundBranched Antisense and siRNA Co‐Assembled Nanoplatform for Combined Gene Silencing and Tumor Therapy
Liu, J., Lu, X., Wu, T., Wu, X., Han, L., & Ding, B. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202011174 · Cited by 65
Makkar, S. K. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1675209 · Cited by 80
“Viral vectors, including adenoviruses, adeno-associated viruses (AAV), and lentiviruses, offer ef fi cient gene delivery by exploiting natural viral infection mechanisms (Naldini, 2015).”
Expanding horizons in complement drug discovery: challenges and emerging strategies
Harris, C. L. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0655-8 · Cited by 63
“There remains untapped potential for modulating complement at the genetic level using cell- or gene-targeting strategies [80, 81].”
BackgroundLiu, X., Wang, B., Li, Y., Hu, Y., Li, X., Yu, T., Ju, Y., Sun, T., Gao, X., & Wei, Y. (2019) · ACS Central Science · doi:10.1021/acscentsci.8b00688 · Cited by 65
Sun, W., Xing, C., Zhao, L., Zhao, P., Yang, G., & Yuan, L. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.03.016 · Cited by 62
The era of gene therapy: From preclinical development to clinical application
Alhakamy, N. A., Curiel, D. T., & Berkland, C. J. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.03.021 · Cited by 76
Molecular nanoparticle-based gene delivery systems
Blanco, J. L. J., Benito, J. M., Mellet, C. O., & Fernández, J. M. G. (2017) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2017.03.012 · Cited by 67
dos Santos Rodrigues, B., Banerjee, A., Kanekiyo, T., & Singh, J. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.06.026 · Cited by 62
“Among the therapies, gene therapy appears promising and offers to counter or replace the malfunctioning/causative gene (Kumar et al., 2016; Naldini, 2015).”
BackgroundZhu, Y., Lin, M., Hu, W., Wang, J., Zhang, Z., Zhang, K., Yu, B., & Xu, F. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200535 · Cited by 62
Carvalho, M. A. B. R., Sepodes, B. M. N., & Martins, A. P. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00182 · Cited by 75
“Moving on to the clinical studies, the oncogenic profile of a gene therapy product is difficult to be predict considering the limited experience in humans with a low number of patients that have been treated with vector to date, the longer follow-up periods that are required and the possibility that the baseline disea…”
BackgroundGene Therapy for Hemoglobinopathies
Cavazzana, M., & Mavilio, F. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.122 · Cited by 71
“Hematopoietic stem/progenitor cells (HSPCs) transduced by lentiviral vectors (LVs) have been used in clinical trials of gene therapy for immunodeficiencies and lysosomal storage disorders, providing strong evidence of safety and long-term efficacy in most cases.(3) In particular.”
MethodCurrent insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo
Xiao, Y., McGuinness, C. S., Doherty-Boyd, W. S., Salmerón‐Sánchez, M., Donnelly, H., & Dalby, M. J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121568 · Cited by 72
“Further, despite the overall safety and efficacy of the CRISPR-Cas 9 system, risks of geno-toxicity and off-target effects do exist, limiting its clinical applications [307,312].”
InfluentialSelf-assembly of peptide nanocapsules by a solvent concentration gradient
Li, H. P., Qian, X., Mohanram, H., Han, X., Qi, H., Zou, G., Yuan, F., Miserez, A., Liu, T., Yang, Q. K., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01654-w · Cited by 69
“The high cargo loading capacity and efficiency of the ICP nanocapsules render them a potentially promising platform for immunotherapy and gene therapy 56,57 .”
Programmable synthetic receptors: the next-generation of cell and gene therapies
Teng, F., Cui, T., Zhou, L., Gao, Q., Zhou, Q., & Li, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01680-5 · Cited by 89
Huang, N.-J., Pishesha, N., Mukherjee, J., Zhang, S., Deshycka, R., Sudaryo, V., Dong, M., Shoemaker, C. B., & Lodish, H. F. (2017) · Nature Communications · doi:10.1038/s41467-017-00448-0 · Cited by 62
Stilhano, R. S., Madrigal, J. L., Wong, K. B., Williams, P. A., Martin, P. K. M., Yamaguchi, F. S. M., Samoto, V. Y., Han, S. W., & Silva, E. A. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.047 · Cited by 63
“Viral vectors remain the most clinically used approach for gene delivery [3], and in particular, lentivectors have been used in an increasing amount of clinical trials [4,5].”
BackgroundPark, A., Hong, P. W.-P., Won, S. T., Thibault, P. A., Vigant, F., Oguntuyo, K. Y., Taft, J. D., & Lee, B. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.57 · Cited by 68
Zhou, X., Lv, J., Li, G., Qian, T., Jiang, H., Xu, J., Cheng, Y., & Hong, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120600 · Cited by 61
Non-Viral Vector-Mediated Gene Therapy for ALS: Challenges and Future Perspectives
Ediriweera, G. R., Chen, L., Yerbury, J. J., Thurecht, K. J., & Vine, K. L. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00297 · Cited by 61
Scharenberg, S. G., Poletto, É., Lucot, K. L., Colella, P., Sheikali, A., Montine, T. J., Porteus, M. H., & Gomez‐Ospina, N. (2020) · Nature Communications · doi:10.1038/s41467-020-17148-x · Cited by 59
Huang, Y.-P., Hung, C., Hsu, Y., Zhong, C.-Y., Wang, W.-R., Chang, C., & Lee, M. (2016) · Nanoscale Research Letters · doi:10.1186/s11671-016-1463-0 · Cited by 59
“With improved vector designs, recent clinical trials have eliminated the safety concerns of gene therapy and demonstrated remarkable therapeutic benefits in inherited diseases of the blood and immune and nervous systems [42].”
BackgroundPrecision medicine, genomics and drug discovery: Table 1.
Cardon, L. R., & Harris, T. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw246 · Cited by 65
Hoffmann, D., Schott, J. W., Geis, F. K., Lange, L., Müller, F.-J., Lenz, D., Zychlinski, D., Steinemann, D., Morgan, M. A., Moritz, T., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.20 · Cited by 72
Nucleic Acid–Based Therapeutics for Parkinson's Disease
Nakamori, M., Junn, E., Mochizuki, H., & Mouradian, M. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00714-7 · Cited by 63
Zhang, X., Men, K., Zhang, Y., Zhang, R., Yang, L., & Duan, X. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s198747 · Cited by 58
Lyu, Y., Cui, D. M., Sun, H., Miao, Y., Duan, H., & Pu, K. (2017) · Angewandte Chemie · doi:10.1002/ange.201705543 · Cited by 56
Gene Therapy Approaches to Hemoglobinopathies
Ferrari, G., Cavazzana, M., & Mavilio, F. (2017) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.06.010 · Cited by 56
Evans, J. H. (2020) · doi:10.1093/oso/9780197519561.001.0001 · Cited by 63
Toward Chemical Perfection of Graphene-Based Gene Carrier via Ugi Multicomponent Assembly Process
Rezaei, A., Akhavan, O., Hashemi, E., & Shamsara, M. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.6b00767 · Cited by 58
Gene Editing of Human Hematopoietic Stem and Progenitor Cells: Promise and Potential Hurdles
Yu, K., Natanson, H., & Dunbar, C. E. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.107 · Cited by 62
Chiang, J.-C., Jiang, J., Newburger, P. E., & Lawrence, J. B. (2018) · Nature Communications · doi:10.1038/s41467-018-07630-y · Cited by 55
Development of “CLAN” Nanomedicine for Nucleic Acid Therapeutics
Xu, C., Iqbal, S., Shen, S., Luo, Y., Yang, X., & Wang, J. (2019) · Small · doi:10.1002/smll.201900055 · Cited by 55
Thang, D. C., Wang, Z., Lü, X., & Xing, B. (2019) · Theranostics · doi:10.7150/thno.33888 · Cited by 56
Miyazaki, T., Uchida, S., Nagatoishi, S., Koji, K., Hong, T., Fukushima, S., Tsumoto, K., Ishihara, K., Kataoka, K., & Cabral, H. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000538 · Cited by 55
Feng, S., Xie, X., Liu, J., Li, A., Wang, Q., Guo, D., Li, S., Li, Y., Wang, Z., Guo, T., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02139-z · Cited by 65
“Despite ongoing improvements in viral vectors [74], their applications in the delivery of CRISPR/Cas system are still hindered by the issues with immunogenicity [75], mutagenesis [76], limited packaging capacity as well as scale-up manufacturing [77, 78].”
BackgroundFan, F., Wang, L., Li, F., Fu, Y., & Xu, H. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b04998 · Cited by 54
The Role of Conditioning in Hematopoietic Stem-Cell Gene Therapy
Bernardo, M. E., & Aiuti, A. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.103 · Cited by 58
Reactive Oxygen Species-Biodegradable Gene Carrier for the Targeting Therapy of Breast Cancer
Ruan, C., Liu, L., Wang, Q., Chen, X., Chen, Q., Lü, Y., Zhang, Y., He, X., Zhang, Y., Guo, Q., et al. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b01712 · Cited by 54
Qu, Y., Sun, F., He, F., Yu, C., Lv, J., Zhang, Q., Dong, L., Yu, C., Wang, J., Zhang, X., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105036 · Cited by 54
Micelleplexes as nucleic acid delivery systems for cancer-targeted therapies
Pereira‐Silva, M., Jarak, I., Alvarez‐Lorenzo, C., Concheiro, Á., Paiva‐Santos, A. C., Veiga, F., & Figueiras, A. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.04.041 · Cited by 60
Xiao, Y., Muhuri, M., Li, S., Qin, W., Xu, G., Luo, L., Li, J., Letizia, A. J., Wang, S. K., Chan, Y. K., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.99052 · Cited by 53
Personalized gene and cell therapy for Duchenne Muscular Dystrophy
Barthélémy, F., & Wein, N. (2018) · Neuromuscular Disorders · doi:10.1016/j.nmd.2018.06.009 · Cited by 60
Cationic nanocarriers: A potential approach for targeting negatively charged cancer cell
Vishwakarma, M., Agrawal, P., Soni, S., Tomar, S., Haider, T., Kashaw, S. K., & Soni, V. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103160 · Cited by 55
Leung, H. M., Chan, M. S., Liu, L. S., Wong, S. W., Lo, T. W., Lau, C., Tin, C., & Lo, P. K. (2018) · ACS Sustainable Chemistry & Engineering · doi:10.1021/acssuschemeng.8b00446 · Cited by 53
Vermeulen, L. M. P., Brans, T., Smedt, S. C. D., Remaut, K., & Braeckmans, K. (2018) · Nano Today · doi:10.1016/j.nantod.2018.06.007 · Cited by 59
Tumor microenvironment as the “regulator” and “target” for gene therapy
Wu, J., Chen, J., Feng, Y., Tian, H., & Chen, X. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3088 · Cited by 60
“com/journ gene therapy plays a significant role in cancer therapy and has the potential to cure cancer.(3,4) Naked nucleic acids are easily degraded by nucleases when applied in vivo.”
BackgroundGene therapy for inborn errors of immunity: past, present and future
Fischer, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00800-6 · Cited by 59
Metal‐Coordinated Polydopamine Structures for Tumor Imaging and Therapy
Wang, L., Song, K., Jiang, C., Liu, S., Huang, S., Huang, Y., Li, X., & Zhao, F. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202401451 · Cited by 60
Yadak, R., Smitt, P. A. E. S., van Gisbergen, M. W., van Til, N. P., & de Coo, I. F. M. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00031 · Cited by 59
“Adeno-associated viral vector gene therapy has been explored in clinical trials for a variety of inherited and acquired diseases (Naldini, 2015).”
BackgroundInside Job: Methods for Delivering Proteins to the Interior of Mammalian Cells
Bruce, V. J., & McNaughton, B. R. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.06.014 · Cited by 57
“Leading clinical trials utilizing viral delivery include hematopoietic stem cell gene therapy, liver-directed gene therapy, T cell immunotherapy for cancer, and retinal gene therapy (Naldini, 2015).”
BackgroundiPSC-Derived Macrophages Effectively Treat Pulmonary Alveolar Proteinosis in Csf2rb-Deficient Mice
Mucci, A., López-Rodríguez, E., Hetzel, M., Liu, S., Suzuki, T., Happle, C., Ackermann, M., Kempf, H., Hillje, R., Kunkiel, J., et al. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.07.006 · Cited by 54
“…system, hematopoietic stem cells (HSCs) traditionally represent the prime target cells for transplantation and gene therapy approaches (Naldini, 2015); however, despite some recent success, the generation of transplantable HSCs from pluripotent cell sources remains problematic…”
CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing
Hossain, M. A. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.001 · Cited by 68
Nanomedicines for dysfunctional macrophage-associated diseases
He, H., Ghosh, S., & Yang, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.032 · Cited by 53
Jaén, M. L., Vilà, L., Elias, I., Jiménez, V., Rodó, J., Maggioni, L., Fernández, R. R. D. G. I., Garcia, M., MUÑOZ, S. A., Callejas, D., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.008 · Cited by 60
Poletti, V., Charrier, S., Corre, G., Gjata, B., Vignaud, A., Zhang, F., Rothe, M., Schambach, A., Gaspar, H. B., Thrasher, A. J., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.03.002 · Cited by 54
CRISPR/Cas9 genome editing technology significantly accelerated herpes simplex virus research
Wang, D., Wang, X.-W., Peng, X., Xiang, Y., Song, S.-B., Wang, Y., Chen, L., Xin, V. W., Lyu, Y.-N., Ji, J., et al. (2018) · Cancer Gene Therapy · doi:10.1038/s41417-018-0016-3 · Cited by 54
“Precise editing of genomic information is essential to understand functions of a given gene and more importantly to introduce useful genes into genomes or replace deficient genes in genomes, termed gene therapy [1].”
BackgroundLee, Y., Mout, R., Luther, D. C., Liu, Y., Castellanos-García, L. J., Burnside, A., Ray, M., Tonga, G. Y., Hardie, J. M., Nagaraj, H., et al. (2019) · Advanced Therapeutics · doi:10.1002/adtp.201900041 · Cited by 57
Rodrigues, B. D. S., Kanekiyo, T., & Singh, J. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00218 · Cited by 54
Lu, X., Fan, S., Cao, M., Liu, D., Xuan, K., & Liu, A. (2024) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-024-00699-2 · Cited by 65
“Through transgenic technique, cells can express specific proteins or RNAs in EVs, which faciliate targeted drug loading and delivery (Naldini 2015).”
Smart dendrimers: Synergizing the targeting of anticancer bioactives
Saluja, V., Mankoo, A., Saraogi, G. K., Tambuwala, M. M., & Mishra, V. K. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.04.014 · Cited by 51
Clinical translation of gene medicine
Wang, F., Qin, Z., Lu, H., He, S., Luo, J. C., Jin, C., & Song, X. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3108 · Cited by 53
“A rational clinical trial design could improve the efficacy and safety of gene therapy.(47) The results obtained in numerous clinical trials have helped provide a better understanding of vector–host interactions and the enhancement of response capacity in the face of vector‐induced adverse events.”
BackgroundAdvanced Nanovehicles-Enabled Delivery Systems of Epigallocatechin Gallate for Cancer Therapy
Li, K., Teng, C., & Min, Q. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.573297 · Cited by 49
“Gene therapy is achieved by counteracting or replacing a malfunctioning gene within the cells, and exhibits great potential to treat various cancers at their genetic roots (Naldini, 2015).”
BackgroundNanovesicle-Mediated Delivery Systems for CRISPR/Cas Genome Editing
Kim, D., Le, Q., Wu, Y., Park, J.-W., & Oh, Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121233 · Cited by 52
Taranejoo, S., Chandrasekaran, R., Cheng, W., & Hourigan, K. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.07.080 · Cited by 48
“Gene therapy continues to encounter some bstacles, however, including the difficulty of transferring genes hrough intricate cellular and tissue barriers (Li, Wei, & Gong, 015; L.M. Li et al., 2015; Naldini, 2015).”
BackgroundDhande, Y. K., Wagh, B. S., Hall, B. C., Sprouse, D., Hackett, P. B., & Reineke, T. M. (2016) · Biomacromolecules · doi:10.1021/acs.biomac.5b01555 · Cited by 48
Advances in the Care of Primary Immunodeficiencies (PIDs): from Birth to Adulthood
Mahlaoui, N., Warnatz, K., Jones, A., Workman, S., & Cant, A. J. (2017) · Journal of Clinical Immunology · doi:10.1007/s10875-017-0401-y · Cited by 48
“constructs based on self-inactivating retroviral or lentiviral vectors [3, 52, 53].”
MethodA Nucleic Acid/Gold Nanorod-Based Nanoplatform for Targeted Gene Editing and Combined Tumor Therapy
Tang, W., Han, L., Lu, X., Wang, Z., Liu, F., Li, Y., Liu, S., Liu, S., Tian, R., Liu, J., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c02122 · Cited by 48
An RNA/DNA hybrid origami-based nanoplatform for efficient gene therapy
Wu, X., Liu, Q. L., Liu, F., Wu, T., Shang, Y., Liu, J., & Ding, B. (2021) · Nanoscale · doi:10.1039/d1nr00517k · Cited by 54
Identification and characterization of in vitro expanded hematopoietic stem cells
James, L. C., Bode, D., Kuciński, I., Cull, A. H., Bain, F. M., Becker, H., Jassinskaja, M., Barile, M., Boyd, G., Belmonte, M., et al. (2022) · EMBO Reports · doi:10.15252/embr.202255502 · Cited by 54
“…outside the body would benefit gene therapy efforts for congenital hematopoietic diseases by preserving HSC function during genetic manipulation (Naldini, 2015) while also seeding in vitro production of virtually limitless numbers of mature blood cells, alleviating the need for blood cell…”
BackgroundChen, X., Dong, T., Hu, Y.-H., Pace, R. D., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Şahin, M., Bonifacino, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164575 · Cited by 41
Mao, M., Wang, L., Chang, C., Rothenberg, K. E., Huang, J., Wang, Y., Hoffman, B. D., Liton, P. B., & Yuan, F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.009 · Cited by 47
Modified-epsilon-polylysine-grafted-PEI-β-cyclodextrin supramolecular carrier for gene delivery
Lv, P., Zhou, C. H., Zhao, Y., Liao, X., & Yang, B. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.02.036 · Cited by 47
“Cationic polymers as nonviral vectors is a major progress in gene therapy in recent years (Naldini, 2015; Piccolo, 2015), efficiently alleviating the viral-based vectors associated shortcomings in the realm of oncogenicity, mutagenicity and immunogenicity.”
BackgroundGene therapy and editing: Novel potential treatments for neuronal channelopathies
Wykes, R. C., & Lignani, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.029 · Cited by 55
“A viral strategy for the delivery of a therapeutic gene or gene-editing tools into a neuron is most likely, although alternatives such as liposomes or nanoparticle mediated delivery can also be considered (Naldini, 2015).”
Liu, X., Li, Y., Sun, X., Muftuoglu, Y., Wang, B., Yu, T., Hu, Y., Ma, L., Xiang, M., Guo, G. F., et al. (2018) · Theranostics · doi:10.7150/thno.24157 · Cited by 47
Recent trends in mucopolysaccharidosis research
Kobayashi, H. (2018) · Journal of Human Genetics · doi:10.1038/s10038-018-0534-8 · Cited by 56
Transfection by cationic gemini lipids and surfactants
Damen, M., Groenen, A., van Dongen, S. F. M., Nolte, R. J. M., Scholte, B. J., & Feiters, M. C. (2018) · MedChemComm · doi:10.1039/c8md00249e · Cited by 48
Liu, B., He, X., Zhuo, R., & Cheng, S. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.10.018 · Cited by 46
Intracellular Photothermal Delivery for Suspension Cells Using Sharp Nanoscale Tips in Microwells
Man, T., Zhu, X., Chow, Y. T., Dawson, E. R., Wen, X., Patananan, A. N., Liu, T. “., Zhao, C., Wu, C., Hong, J. S., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b06025 · Cited by 48
Chen, X., Dong, T., Hu, Y.-H., Shaffo, F. C., Belur, N. R., Mazzulli, J., & Gray, S. (2022) · Journal of Clinical Investigation · doi:10.1172/jci146286 · Cited by 40
Xu, H., Chang, J., Wu, H., Wang, H., Xie, W., Li, Y., Li, X., Zhang, Y., & Fan, L. (2023) · Small · doi:10.1002/smll.202207204 · Cited by 52
Gene Therapy Strategies to Restore ER Proteostasis in Disease
Valenzuela, V., Jackson, K. L., Sardi, S. P., & Hetz, C. A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.004 · Cited by 56
Gene Therapy for Liver Cancers: Current Status from Basic to Clinics
Kamimura, K., Yokoo, T., Abé, H., & Terai, S. (2019) · Cancers · doi:10.3390/cancers11121865 · Cited by 49
“On the basis of the progress of gene therapy described above, various clinical trials are ongoing [28] and gene therapy has become a realistic treatment option for a wide variety of cancers [25,26].”
BackgroundStructural and cellular biology of adeno-associated virus attachment and entry
Zengel, J. R., & Carette, J. E. (2020) · Advances in virus research · doi:10.1016/bs.aivir.2020.01.002 · Cited by 54
Tailor‐Made Nanomaterials for Diagnosis and Therapy of Pancreatic Ductal Adenocarcinoma
Hu, X., Xia, F., Lee, J., Li, F., Lu, X., Zhuo, X., Nie, G., & Ling, D. (2021) · Advanced Science · doi:10.1002/advs.202002545 · Cited by 47
Remote Control of Light-Triggered Virotherapy
Tseng, S. ‐., Huang, K., Kempson, I. M., Kao, S.-H., Liu, M.-C., Yang, S., Liao, Z., & Yang, P. (2016) · ACS Nano · doi:10.1021/acsnano.6b06051 · Cited by 44
Batasheva, S., Kryuchkova, M., Fakhrullin, R., Cavallaro, G. P., Lazzara, G., Akhatova, F. S., Nigamatzyanova, L., Evtugyn, V. G., Rozhina, E. V., & Fakhrullin, R. F. (2020) · Molecules · doi:10.3390/molecules25153557 · Cited by 44
“However, despite a rapid advancement and promising results of gene therapies based on modified viral vectors [5] some concerns remain about their safety [6].”
BackgroundAdvances in siRNA delivery strategies for the treatment of MDR cancer
Subhan, M. A., Attia, S. A., & Torchilin, V. P. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119337 · Cited by 49
Retrieval of vector integration sites from cell-free DNA
Cesana, D., Calabria, A., Rudilosso, L., Gallina, P., Benedicenti, F., Spinozzi, G., Schiroli, G., Magnani, A., Acquati, S., Fumagalli, F., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01389-4 · Cited by 44
Self-citation
Metadata
- Authors
- Naldini, L.
- Affiliations
- Vita-Salute San Raffaele University (IT)
- Corresponding author
- Naldini, Luigi
- ORCID
- Naldini, Luigi
- Venue
- Nature
- Published
- 2015-10
- Volume
- 526
- Issue
- 7573
- Pages
- 351-360
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1902159756
- Semantic Scholar
- 334eb76dbe52abdfcdb4be9aa772d017378a95d3
- Cited by
- 1,184
- References
- 124
- Citations by year
- 2026: 67 · 2025: 77 · 2024: 59 · 2023: 75 · 2022: 76 · 2021: 99 · 2020: 141 · 2019: 132 · 2018: 182 · 2017: 158 · 2016: 109 · 2015: 7
- FWCI
- 19.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Fondazione Telethon
- Ministero della Salute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Keywords
- gene therapy, clinical trials, gene therapy vectors, genome editing, inherited mutations, stem cell therapy, tissue regeneration, cancer immunotherapy, gene therapy safety
- MeSH terms
- Clinical Trials as Topic, Hematopoietic Stem Cells, Humans, Immunotherapy, Liver, Neoplasms, Organ Specificity, T-Lymphocytes, Genetic Therapy, Gene Targeting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.